FMC Gardendale is a medicare approved dialysis facility center in Gardendale, Alabama and it has 17 dialysis stations. It is located in Jefferson county at 592 Fieldstown Road, Gardendale, AL, 35071. You can reach out to the office of FMC Gardendale at (205) 608-3653. This dialysis clinic is managed and/or owned by Fresenius Medical Care. FMC Gardendale has the following ownership type - Profit. It was first certified by medicare in December, 2003. The medicare id for this facility is 012612 and it accepts patients under medicare ESRD program.
| Name | FMC Gardendale |
|---|---|
| Location | 592 Fieldstown Road, Gardendale, Alabama |
| No. of Dialysis Stations | 17 |
| Medicare ID | 012612 |
| Managed By | Fresenius Medical Care |
| Ownership Type | Profit |
| Late Shifts | Yes |
| 592 Fieldstown Road, Gardendale, Alabama, 35071 | |
| (205) 608-3653 | |
News Archive
VisiVite®, a world leader in eye vitamins, today announced its launch of a gentle new macular health formula: AREDS2 Silver®. Based on the National Eye Institute's Age-Related Eye Disease Studies (AREDS and AREDS2), AREDS2 Silver supplies antioxidants for macular health without the high levels of zinc that may cause issues in those with zinc sensitivities and allergies.
The Alcon Independent Director Committee (the "Committee") of Alcon, Inc. today announced that RiskMetrics Group, Inc., a global leader in risk management, corporate governance and financial research and analysis, has raised concerns about the adequacy of the merger proposal by Novartis AG ("Novartis") to Alcon's minority shareholders and the legality of any attempt by Novartis to unilaterally impose a full takeover of Alcon.
Today Bjond, Inc. announced that it closed $3.25 million in Series A financing. Draper Triangle Ventures led the round, joined by co-investors TriStar Technology Ventures and Hopen Life Science Ventures.
Researchers at Western University are using cutting-edge genetic mutation-analysis software developed in their lab to interpret mutations in tumour genome that may provide insight into determining which breast cancer tumours are more likely spread to other parts of the body and which ones won't.
› Verified 9 days ago
| NPI Number | 1487756862 |
| Organization Name | Fresenius Medical Care Of Gardendale |
| Doing Business As | Bio-medical Applications Of Alabama, Inc. |
| Address | 592 Fieldstown Rd Gardendale, Alabama, 35071 |
| Phone Number | (205) 608-3653 |
News Archive
VisiVite®, a world leader in eye vitamins, today announced its launch of a gentle new macular health formula: AREDS2 Silver®. Based on the National Eye Institute's Age-Related Eye Disease Studies (AREDS and AREDS2), AREDS2 Silver supplies antioxidants for macular health without the high levels of zinc that may cause issues in those with zinc sensitivities and allergies.
The Alcon Independent Director Committee (the "Committee") of Alcon, Inc. today announced that RiskMetrics Group, Inc., a global leader in risk management, corporate governance and financial research and analysis, has raised concerns about the adequacy of the merger proposal by Novartis AG ("Novartis") to Alcon's minority shareholders and the legality of any attempt by Novartis to unilaterally impose a full takeover of Alcon.
Today Bjond, Inc. announced that it closed $3.25 million in Series A financing. Draper Triangle Ventures led the round, joined by co-investors TriStar Technology Ventures and Hopen Life Science Ventures.
Researchers at Western University are using cutting-edge genetic mutation-analysis software developed in their lab to interpret mutations in tumour genome that may provide insight into determining which breast cancer tumours are more likely spread to other parts of the body and which ones won't.
› Verified 9 days ago
| NPI Number | 1588602221 |
| Organization Name | Gardendale Dialysis Facility |
| Doing Business As | Bio-medical Applications Of Alabama Inc |
| Address | 592 Fieldstown Rd Gardendale, Alabama, 35071 |
| Phone Number | (205) 608-3653 |
News Archive
VisiVite®, a world leader in eye vitamins, today announced its launch of a gentle new macular health formula: AREDS2 Silver®. Based on the National Eye Institute's Age-Related Eye Disease Studies (AREDS and AREDS2), AREDS2 Silver supplies antioxidants for macular health without the high levels of zinc that may cause issues in those with zinc sensitivities and allergies.
The Alcon Independent Director Committee (the "Committee") of Alcon, Inc. today announced that RiskMetrics Group, Inc., a global leader in risk management, corporate governance and financial research and analysis, has raised concerns about the adequacy of the merger proposal by Novartis AG ("Novartis") to Alcon's minority shareholders and the legality of any attempt by Novartis to unilaterally impose a full takeover of Alcon.
Today Bjond, Inc. announced that it closed $3.25 million in Series A financing. Draper Triangle Ventures led the round, joined by co-investors TriStar Technology Ventures and Hopen Life Science Ventures.
Researchers at Western University are using cutting-edge genetic mutation-analysis software developed in their lab to interpret mutations in tumour genome that may provide insight into determining which breast cancer tumours are more likely spread to other parts of the body and which ones won't.
› Verified 9 days ago
| NPI Number | 1730357385 |
| Organization Name | Ckd Services Of Gardendale |
| Doing Business As | Fresnius Medical Care Comprehensive Ckd Services Inc |
| Address | 592 Fieldstown Rd Gardendale, Alabama, 35071 |
| Phone Number | (205) 608-3653 |
News Archive
VisiVite®, a world leader in eye vitamins, today announced its launch of a gentle new macular health formula: AREDS2 Silver®. Based on the National Eye Institute's Age-Related Eye Disease Studies (AREDS and AREDS2), AREDS2 Silver supplies antioxidants for macular health without the high levels of zinc that may cause issues in those with zinc sensitivities and allergies.
The Alcon Independent Director Committee (the "Committee") of Alcon, Inc. today announced that RiskMetrics Group, Inc., a global leader in risk management, corporate governance and financial research and analysis, has raised concerns about the adequacy of the merger proposal by Novartis AG ("Novartis") to Alcon's minority shareholders and the legality of any attempt by Novartis to unilaterally impose a full takeover of Alcon.
Today Bjond, Inc. announced that it closed $3.25 million in Series A financing. Draper Triangle Ventures led the round, joined by co-investors TriStar Technology Ventures and Hopen Life Science Ventures.
Researchers at Western University are using cutting-edge genetic mutation-analysis software developed in their lab to interpret mutations in tumour genome that may provide insight into determining which breast cancer tumours are more likely spread to other parts of the body and which ones won't.
› Verified 9 days ago
| Dialysis patients with Hemoglobin data | 29 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 17 |
News Archive
VisiVite®, a world leader in eye vitamins, today announced its launch of a gentle new macular health formula: AREDS2 Silver®. Based on the National Eye Institute's Age-Related Eye Disease Studies (AREDS and AREDS2), AREDS2 Silver supplies antioxidants for macular health without the high levels of zinc that may cause issues in those with zinc sensitivities and allergies.
The Alcon Independent Director Committee (the "Committee") of Alcon, Inc. today announced that RiskMetrics Group, Inc., a global leader in risk management, corporate governance and financial research and analysis, has raised concerns about the adequacy of the merger proposal by Novartis AG ("Novartis") to Alcon's minority shareholders and the legality of any attempt by Novartis to unilaterally impose a full takeover of Alcon.
Today Bjond, Inc. announced that it closed $3.25 million in Series A financing. Draper Triangle Ventures led the round, joined by co-investors TriStar Technology Ventures and Hopen Life Science Ventures.
Researchers at Western University are using cutting-edge genetic mutation-analysis software developed in their lab to interpret mutations in tumour genome that may provide insight into determining which breast cancer tumours are more likely spread to other parts of the body and which ones won't.
› Verified 9 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 76 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 655 |
| Percentage of adult patients getting regular hemodialysis at the center | 95 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
VisiVite®, a world leader in eye vitamins, today announced its launch of a gentle new macular health formula: AREDS2 Silver®. Based on the National Eye Institute's Age-Related Eye Disease Studies (AREDS and AREDS2), AREDS2 Silver supplies antioxidants for macular health without the high levels of zinc that may cause issues in those with zinc sensitivities and allergies.
The Alcon Independent Director Committee (the "Committee") of Alcon, Inc. today announced that RiskMetrics Group, Inc., a global leader in risk management, corporate governance and financial research and analysis, has raised concerns about the adequacy of the merger proposal by Novartis AG ("Novartis") to Alcon's minority shareholders and the legality of any attempt by Novartis to unilaterally impose a full takeover of Alcon.
Today Bjond, Inc. announced that it closed $3.25 million in Series A financing. Draper Triangle Ventures led the round, joined by co-investors TriStar Technology Ventures and Hopen Life Science Ventures.
Researchers at Western University are using cutting-edge genetic mutation-analysis software developed in their lab to interpret mutations in tumour genome that may provide insight into determining which breast cancer tumours are more likely spread to other parts of the body and which ones won't.
› Verified 9 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at FMC Gardendale with elevated calcium levels.
| Patients with hypercalcemia | 80 |
| Hypercalcemia patient months | 693 |
| Patients with Serumphosphor | 84 |
| Patients with Serumphosphor less than 3.5 mg/dL | 8 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 21 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 27 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 28 |
| Patients with Serumphosphor greater than 7 mg/dL | 16 |
News Archive
VisiVite®, a world leader in eye vitamins, today announced its launch of a gentle new macular health formula: AREDS2 Silver®. Based on the National Eye Institute's Age-Related Eye Disease Studies (AREDS and AREDS2), AREDS2 Silver supplies antioxidants for macular health without the high levels of zinc that may cause issues in those with zinc sensitivities and allergies.
The Alcon Independent Director Committee (the "Committee") of Alcon, Inc. today announced that RiskMetrics Group, Inc., a global leader in risk management, corporate governance and financial research and analysis, has raised concerns about the adequacy of the merger proposal by Novartis AG ("Novartis") to Alcon's minority shareholders and the legality of any attempt by Novartis to unilaterally impose a full takeover of Alcon.
Today Bjond, Inc. announced that it closed $3.25 million in Series A financing. Draper Triangle Ventures led the round, joined by co-investors TriStar Technology Ventures and Hopen Life Science Ventures.
Researchers at Western University are using cutting-edge genetic mutation-analysis software developed in their lab to interpret mutations in tumour genome that may provide insight into determining which breast cancer tumours are more likely spread to other parts of the body and which ones won't.
› Verified 9 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 48 |
| Patient months included in arterial venous fistula and catheter summaries | 384 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 57 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 9 |
News Archive
VisiVite®, a world leader in eye vitamins, today announced its launch of a gentle new macular health formula: AREDS2 Silver®. Based on the National Eye Institute's Age-Related Eye Disease Studies (AREDS and AREDS2), AREDS2 Silver supplies antioxidants for macular health without the high levels of zinc that may cause issues in those with zinc sensitivities and allergies.
The Alcon Independent Director Committee (the "Committee") of Alcon, Inc. today announced that RiskMetrics Group, Inc., a global leader in risk management, corporate governance and financial research and analysis, has raised concerns about the adequacy of the merger proposal by Novartis AG ("Novartis") to Alcon's minority shareholders and the legality of any attempt by Novartis to unilaterally impose a full takeover of Alcon.
Today Bjond, Inc. announced that it closed $3.25 million in Series A financing. Draper Triangle Ventures led the round, joined by co-investors TriStar Technology Ventures and Hopen Life Science Ventures.
Researchers at Western University are using cutting-edge genetic mutation-analysis software developed in their lab to interpret mutations in tumour genome that may provide insight into determining which breast cancer tumours are more likely spread to other parts of the body and which ones won't.
› Verified 9 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 55 |
| Hospitalization Rate in facility | 154.5 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 286.8 |
| Hospitalization Rate: Lower Confidence Limit | 86.9 |
News Archive
VisiVite®, a world leader in eye vitamins, today announced its launch of a gentle new macular health formula: AREDS2 Silver®. Based on the National Eye Institute's Age-Related Eye Disease Studies (AREDS and AREDS2), AREDS2 Silver supplies antioxidants for macular health without the high levels of zinc that may cause issues in those with zinc sensitivities and allergies.
The Alcon Independent Director Committee (the "Committee") of Alcon, Inc. today announced that RiskMetrics Group, Inc., a global leader in risk management, corporate governance and financial research and analysis, has raised concerns about the adequacy of the merger proposal by Novartis AG ("Novartis") to Alcon's minority shareholders and the legality of any attempt by Novartis to unilaterally impose a full takeover of Alcon.
Today Bjond, Inc. announced that it closed $3.25 million in Series A financing. Draper Triangle Ventures led the round, joined by co-investors TriStar Technology Ventures and Hopen Life Science Ventures.
Researchers at Western University are using cutting-edge genetic mutation-analysis software developed in their lab to interpret mutations in tumour genome that may provide insight into determining which breast cancer tumours are more likely spread to other parts of the body and which ones won't.
› Verified 9 days ago
The rate of readmission show you whether patients who were being treated regularly at FMC Gardendale were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 22.2 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 35.3 |
| Readmission Rate: Lower Confidence Limit | 12.2 |
News Archive
VisiVite®, a world leader in eye vitamins, today announced its launch of a gentle new macular health formula: AREDS2 Silver®. Based on the National Eye Institute's Age-Related Eye Disease Studies (AREDS and AREDS2), AREDS2 Silver supplies antioxidants for macular health without the high levels of zinc that may cause issues in those with zinc sensitivities and allergies.
The Alcon Independent Director Committee (the "Committee") of Alcon, Inc. today announced that RiskMetrics Group, Inc., a global leader in risk management, corporate governance and financial research and analysis, has raised concerns about the adequacy of the merger proposal by Novartis AG ("Novartis") to Alcon's minority shareholders and the legality of any attempt by Novartis to unilaterally impose a full takeover of Alcon.
Today Bjond, Inc. announced that it closed $3.25 million in Series A financing. Draper Triangle Ventures led the round, joined by co-investors TriStar Technology Ventures and Hopen Life Science Ventures.
Researchers at Western University are using cutting-edge genetic mutation-analysis software developed in their lab to interpret mutations in tumour genome that may provide insight into determining which breast cancer tumours are more likely spread to other parts of the body and which ones won't.
› Verified 9 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at FMC Gardendale get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | .43 (As Expected) |
| SIR: Upper Confidence Limit | 1.41 |
| SIR: Lower Confidence Limit | .07 |
News Archive
VisiVite®, a world leader in eye vitamins, today announced its launch of a gentle new macular health formula: AREDS2 Silver®. Based on the National Eye Institute's Age-Related Eye Disease Studies (AREDS and AREDS2), AREDS2 Silver supplies antioxidants for macular health without the high levels of zinc that may cause issues in those with zinc sensitivities and allergies.
The Alcon Independent Director Committee (the "Committee") of Alcon, Inc. today announced that RiskMetrics Group, Inc., a global leader in risk management, corporate governance and financial research and analysis, has raised concerns about the adequacy of the merger proposal by Novartis AG ("Novartis") to Alcon's minority shareholders and the legality of any attempt by Novartis to unilaterally impose a full takeover of Alcon.
Today Bjond, Inc. announced that it closed $3.25 million in Series A financing. Draper Triangle Ventures led the round, joined by co-investors TriStar Technology Ventures and Hopen Life Science Ventures.
Researchers at Western University are using cutting-edge genetic mutation-analysis software developed in their lab to interpret mutations in tumour genome that may provide insight into determining which breast cancer tumours are more likely spread to other parts of the body and which ones won't.
› Verified 9 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether FMC Gardendale's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 45 |
| Transfusion Rate in facility | 43.5 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 126.1 |
| Transfusion Rate: Lower Confidence Limit | 17.1 |
News Archive
VisiVite®, a world leader in eye vitamins, today announced its launch of a gentle new macular health formula: AREDS2 Silver®. Based on the National Eye Institute's Age-Related Eye Disease Studies (AREDS and AREDS2), AREDS2 Silver supplies antioxidants for macular health without the high levels of zinc that may cause issues in those with zinc sensitivities and allergies.
The Alcon Independent Director Committee (the "Committee") of Alcon, Inc. today announced that RiskMetrics Group, Inc., a global leader in risk management, corporate governance and financial research and analysis, has raised concerns about the adequacy of the merger proposal by Novartis AG ("Novartis") to Alcon's minority shareholders and the legality of any attempt by Novartis to unilaterally impose a full takeover of Alcon.
Today Bjond, Inc. announced that it closed $3.25 million in Series A financing. Draper Triangle Ventures led the round, joined by co-investors TriStar Technology Ventures and Hopen Life Science Ventures.
Researchers at Western University are using cutting-edge genetic mutation-analysis software developed in their lab to interpret mutations in tumour genome that may provide insight into determining which breast cancer tumours are more likely spread to other parts of the body and which ones won't.
› Verified 9 days ago
The rate of mortality show you whether patients who were being treated regularly at FMC Gardendale lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 253 |
| Mortality Rate in facility | 17.9 (As Expected) |
| Mortality Rate: Upper Confidence Limit | 24.2 |
| Mortality Rate: Lower Confidence Limit | 12.8 |
News Archive
VisiVite®, a world leader in eye vitamins, today announced its launch of a gentle new macular health formula: AREDS2 Silver®. Based on the National Eye Institute's Age-Related Eye Disease Studies (AREDS and AREDS2), AREDS2 Silver supplies antioxidants for macular health without the high levels of zinc that may cause issues in those with zinc sensitivities and allergies.
The Alcon Independent Director Committee (the "Committee") of Alcon, Inc. today announced that RiskMetrics Group, Inc., a global leader in risk management, corporate governance and financial research and analysis, has raised concerns about the adequacy of the merger proposal by Novartis AG ("Novartis") to Alcon's minority shareholders and the legality of any attempt by Novartis to unilaterally impose a full takeover of Alcon.
Today Bjond, Inc. announced that it closed $3.25 million in Series A financing. Draper Triangle Ventures led the round, joined by co-investors TriStar Technology Ventures and Hopen Life Science Ventures.
Researchers at Western University are using cutting-edge genetic mutation-analysis software developed in their lab to interpret mutations in tumour genome that may provide insight into determining which breast cancer tumours are more likely spread to other parts of the body and which ones won't.
› Verified 9 days ago
News Archive
VisiVite®, a world leader in eye vitamins, today announced its launch of a gentle new macular health formula: AREDS2 Silver®. Based on the National Eye Institute's Age-Related Eye Disease Studies (AREDS and AREDS2), AREDS2 Silver supplies antioxidants for macular health without the high levels of zinc that may cause issues in those with zinc sensitivities and allergies.
The Alcon Independent Director Committee (the "Committee") of Alcon, Inc. today announced that RiskMetrics Group, Inc., a global leader in risk management, corporate governance and financial research and analysis, has raised concerns about the adequacy of the merger proposal by Novartis AG ("Novartis") to Alcon's minority shareholders and the legality of any attempt by Novartis to unilaterally impose a full takeover of Alcon.
Today Bjond, Inc. announced that it closed $3.25 million in Series A financing. Draper Triangle Ventures led the round, joined by co-investors TriStar Technology Ventures and Hopen Life Science Ventures.
Researchers at Western University are using cutting-edge genetic mutation-analysis software developed in their lab to interpret mutations in tumour genome that may provide insight into determining which breast cancer tumours are more likely spread to other parts of the body and which ones won't.
› Verified 9 days ago